New EU products in 2014: two firsts, nine novel anticancers, and a troupe of orphans
This article was originally published in SRA
Executive Summary
Thirty-four new active substances/biologics were among the 80-odd products approved for marketing by the European Commission in 2014, many of them for rare or difficult to treat diseases1,2. Ten of the new products were biologics, the remainder being new chemical entities.
You may also be interested in...
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.